BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Business

  Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges

  Stephen Majors from the Alliance for Regenerative Medicine, which hosts the conference, spoke with BioSpace about what the more than 2,000 attendees can expect to learn next week in Phoenix about the pressing issues confronting the industry.

  October 3, 2024

   · 

  7 min read

   · 

  Greg Slabodkin
• 

  IRA

  CMS Releases Updated Medicare Drug Price Negotiation Guidance, Offers More Flexible Timeline

  The adjusted guidelines will provide drugmakers with more opportunities to engage with the Centers for Medicare and Medicaid Services regarding the initial maximum fair price offers, according to the agency.

  October 3, 2024

   · 

  1 min read

   · 

  Tristan Manalac
• 

  BIOSECURE Act

  WuXi Mulls Sale of Some US, European Operations: FT

  The Financial Times reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.

  October 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Supply chain

  Lilly’s Tirzepatide No Longer on FDA Drug Shortage List

  BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.

  October 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Infectious disease

  Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries

  Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.

  October 3, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Smith+Nephew raises the bar in knee revisions by launching new LEGION™ Hinged Knee System with OXINIUM™ Technology

  October 3, 2024

   · 

  8 min read
• Press Releases

  DepYmed to Present at the 9th World Rett Syndrome Congress

  October 3, 2024

   · 

  4 min read
• Press Releases

  Koning Health Welcomes Dr. David Bodne and Dr. Richard Reaven as Co-Chief Medical Officers

  October 3, 2024

   · 

  2 min read
• Press Releases

  BioLab Holdings, Inc. Launches New Triple Layered Amniotic Skin Substitute Product

  October 3, 2024

   · 

  2 min read
• Press Releases

  Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2024

  October 3, 2024

   · 

  2 min read